WASHINGTON, Nov 18 - Top Democrats in the U.S. House of Representatives have asked government investigators to assess recent increases in brand-name prescription drug prices, seeking a "benchmark" as Congress finalizes health reform overhaul.
The leaders of the House Ways and Means and Energy and Commerce Committees, in a letter to the Government Accountability Office sent late Tuesday, said they would probably seek another analysis of pricing trends after reform measures are implemented.
If you believe an article violates your rights or the rights of others, please contact us.